Journal article
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction
Abstract
The death rate of patients with ST-segment elevation myocardial infarction (STEMI) remains substantial. Fondaparinux is a synthetic selective Factor Xa inhibitor with a high efficacy and good safety, in terms of bleeding risk, in the prevention and treatment of venous thromboembolism, and in the treatment of non-ST elevation acute coronary syndromes (OASIS-5). The OASIS-6 trial was a randomized, double-blind trial comparing fondaparinux 2.5 mg …
Authors
Turpie AG
Journal
Vascular Health and Risk Management, Vol. 2, No. 4, pp. 371–378
Publisher
Taylor & Francis
Publication Date
December 2006
DOI
10.2147/vhrm.s24371
ISSN
1176-6344